

Hyaluronan Enzyme-Linked Immunosorbent Assay Kit (HA – ELISA)

K-1200 (96 tests)

Support: echelon@echelon-inc.com

<u>Description</u>: The Hyaluronan Enzyme-Linked Immunosorbent Assay (HA ELISA), a competitive 96-well assay, that offers a simple, effective method for determining Hyaluronic Acid (HA) levels in human and animal biological fluids or cell supernatants.

Storage: Store kit at 4 °C for up to six months

Materials Provided

Catalog #	Description	Quantity
K-1201	Detection Plate (12 HA-coated 8-well microwell strips w/ frame)	1 Plate
K-1202	HA Standard (3200 ng/mL HA standard solution)	1 mL
K-1203	HA Detector	< 500 µL
K-1204	Diluent (10X)	10 mL
K-PBST3	10X Wash Buffer	30 mL
K-1206	Enzyme	< 100 µL
K-1208	Substrate Buffer	12 mL
K-1209	Stop Solution	8 mL
Incubation Plate	Natural 96-well polypropylene Plate	1 Plate
	Substrate Pellet (p-Nitrophenyl Phosphate)	1 Pellet
	Plate Seals Clear acetate sheet, 1 side Adhesive	2 Seals

Quick Protocol

Prepare reagents and samples
Setup HA standards, controls and samples with working HA Detector in Incubation Plate
Incubate for 1 hour at 37°C
-
Transfer 100 µL/well mixture from Incubation Plate to Detection Plate
Incubate for 30 min at 4°C
West Dates Co. Blate the co. Co.
Wash Detection Plate three times
Apply 100 μL/well working Enzyme and Incubate for 30 min at 37°C
Wash Detection Plate three times
Apply 100 µL/well working Substrate Solution and incubate in dark for 30 min at RT
Add 50 µL/well Stop Solution and read absorbance at 405 nm

Additional Materials Provided by User

- 37 °C Incubator
- Pipettes (capable of delivering between 5 and 1,000 μL with appropriate tips)
- Multichannel pipettes
- Absorbance microplate reader capable of reading at 405 nm

This kit and all non-radioactive, competitive assays for determining phosphoinositide-3-kinase (PI3-K) activity are protected by Echelon Biosciences Inc. U.S. Patent 7,067,269. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser's own internal research. For inquiries, email echelon@echelon-inc.com

TM TM

Technical Data Sheet, Rev 16c, 06-25-25 – For research use only. Not intended for diagnostic or therapeutic use. Page 1



Background

Hyaluronic acid (HA) is a high molecular weight anionic polysaccharide (1,000-10,000 kD) composed of repeating disaccharides of β (1-4)glucuronic acid and β (1-3)N-acetylglucosamine and is one of several glycosaminoglycan (GAG) components of the extracellular matrix (ECM) of connective tissue (1). Each disaccharide dimer is referred to as one unit and has an approximate molecular weight (MW) of 450 D. Depending on the tissue source, the polymer can consist of 2,000 to 25,000 units (2). HA is an extremely large molecule not necessarily in its molecular weight but in the space that it occupies in solution which lends to its remarkable viscoelastic properties, lending to its importance in joint lubrication (3).


Several functions of HA have been described including influencing the hydration and physical properties of tissues; and its ECM (extra- cellular matrix) interactions which affect tissue structure, assembly and facilitation of cell movement and behavior.

Free HA is transported from the lymph to the circulation with an estimated half-life in serum of 2-5 minutes. HA is taken up by the liver in sinusoidal endothelial cells (90%) and the kidneys (10%) where it is degraded and recycled (4,5). Many chronic liver diseases, including infection (hepatitis B or C), toxicity (alcohol and drugs), genetic (hemochromatosis), autoimmunity, and malignancy, result in liver inflammation which can progress to liver fibrosis and cirrhosis (6). Each of these cause impairments of liver function and result in a rapid increase in circulating HA levels (4). Data indicates a relationship between HA levels, local inflammation and severity of disease (6).

Recent publications have shown that HA levels in urine are indicative of bladder cancer, that HA levels are directly correlated to liver disease and suggests enhanced breakdown of HA in the lungs of patients with chronic obstructive pulmonary disease (COPD). In addition, serum levels of HA have been found to be elevated in patients with rheumatoid arthritis (7).

Assay Design

The HA-ELISA is a quantitative enzyme-linked immunoassay designed for the in vitro measurement of HA levels in human or animal biological fluids (blood, serum, urine, diffusate, synovial fluid). This simple protocol requires 3 hours.



The HA-ELISA is a competitive ELISA in which the colorimetric signal is inversely proportional to the amount of HA present in the

sample. Samples to be assayed are first mixed with the HA Detector, and then added to the HA ELISA plate for competitive binding. An enzyme-linked antibody and colorimetric detection is used to detect the HA detector bound to the plate. The concentration of HA in the sample is determined using a standard curve of known amounts of HA. The enzyme /substrate system is a colorimetric assay comprised of alkaline phosphatase / pNPP phosphatase substrate. It should be read at 405 nm.

The size of HA polymers is variable depending on tissue source. However, the sensitivity of the HA ELISA does not depend on the MW of the HA molecule except in the lower MW range (<25 dimers). The HA ELISA works best with HA molecules that are greater than 25 repeating units (dimers) to determine the relative concentration of HA independent of MW.

Assay Notes

- We suggest the HA Standard dilution series be run in triplicate for best results.
- It is recommended that serum and plasma samples be analyzed with no dilution or at a maximum 2-fold dilution in the provided Diluent.
- 3. When analyzing biologic samples, we advise running a known normal (low) HA sample and a disease (high) HA sample in conjunction with your unknown samples. These will serve as positive and negative controls to distinguish between normal healthy samples and disease samples.
- 4. Reference HA Values: Normal HA levels in serum from healthy blood donors are less than 120 ng/mL. Serum HA levels are elevated in several disease states including hepatitis (greater than 160 ng/mL) and cirrhosis (greater than 250ng/mL).
 ** Important Note: The above values are the suggested values based on literature observations. At times, the values measured using the Echelon Hyaluronic Acid ELISA assay have been 2-3-fold higher than those

values based on literature observations. At times, the values measured using the Echelon Hyaluronic Acid ELISA assay have been 2-3-fold higher than those expected from the literature. As a result, we strongly advise users to utilize known reference samples indicative of both normal and disease states to establish relevant Hyaluronic acid levels. This will allow the user to differentiate between normal and disease state Hyaluronic Acid samples in a qualitative fashion.**

Protocols

Note: all reagents of the kit, once at working concentration, can be stored at -20 °C for up to 2 months and can handle at least 1 freeze/defrost cycle. Reagents at working concentration, except the working Substrate Solution, can also be stored at 4 °C for 2 weeks. The working Substrate Solution can be used for up to 48 hours when stored at 4 °C. Additional Substrate Buffer (K-1208) and pellet can be purchased under catalog number K-1208T.

Reagent Preparation

 1X Diluent: The Diluent is supplied as a 10X concentrated solution (K-1204). Dilute the required amount to a 1X working Diluent with dH2O prior to beginning assay. Typically, around 30-35 mL of Diluent

Technical Data Sheet, Rev 16c, 06-25-25 - For research use only. Not intended for diagnostic or therapeutic use. Page 2



Ph: 866-588-0455 Fax: 801-588-0497 **echelon-inc.com**



- is required to run a full assay. For 30 mL of 1X Diluent, add 3 mL of the 10X Diluent to 27 mL of dH2O.
- 2. HA Standards: Gently mix HA standard. Make 2-fold serial dilutions of the HA Standard (K-1202) using the Diluent to obtain standards of 1600, 800, 400, 200, 100, and 50 ng/mL (Standards may be diluted in the incubation plate, following the diagram below).
- Working Detector: Dilute Detector (K-1203) by adding 6 mL Diluent. The volume of the Detector provided is small and the bottle may appear empty.
- 4. Working Enzyme: Dilute Enzyme (K-1206) by adding 12 mL Diluent. The volume of Enzyme provided is small and the bottle may appear empty.
- 1X Wash Buffer: Add the 10X Wash Buffer (K-PBST3) to 270 mL deionized water for a 1X Wash Buffer solution. Final volume = 300 mL
- 6. Working Substrate Solution: Dissolve Substrate Pellet in 12 mL Substrate Buffer (K-1208).

Assay Procedure

- 7. Set up the Incubation Plate (natural 96-well plate) as illustrated. Each well should contain 150 μL.
 - a. Add 100 μL of Standards and samples into corresponding wells.
 - Add 150 µL of Diluent to the Blank control wells and 100 µL of Diluent to the Zero HA control wells.
 - c. Add 50 μ L of working HA Detector to all wells except the Blank control wells.
- 8. Mix the plate gently, cover with plate seal and incubate for one hour at 37 °C.
- Following the incubation step, transfer 100 μL of controls and samples from the Incubation Plate to the corresponding wells of the Detection Plate (K-1201). This is easily accomplished with a multichannel pipettor.
- 10. Once the transfer is complete, mix the Detection Plate by gently tapping. Cover with a plate seal and incubate at 4 °C for 30 minutes.
- 11. Shake out the solution from the Detection Plate. Wash the plate 3 times with 200 µL of 1X Wash Buffer.

- Ensure all wash buffer is removed from the plate by inverting the plate and blotting it out on absorbent paper.
- 12. Add 100 µL of working Enzyme (K-1206) to each well of the Detection Plate.
- 13. Mix the Detection Plate gently, cover with plate seal and incubate at 37 °C for 30 minutes.
- 14. Repeat wash step #11.
- 15. Add 100 μ L working Substrate Solution (K-1208) to each well of the Detection Plate. Incubate plate in dark at room temperature for 30 min.
- Stop the reaction by adding 50 μL Stop Solution (K-1209) to each well. Read the detection plate to measure the absorbance at 405 nm.

Quantification of Samples

Generate a best fit curve for the standards to interpolate relative sample values. (See figure 1.)

Nonlinear Regression Sigmoidal Dose Response (variable slope)




Figure 1: HA competitive ELISA standard curve was generated using nonlinear regression analysis with GraphPad Prism software. A sigmoidal dose response-variable slope curve (four-parameter) analysis was utilized.

Suggested Incubation Plate Layout

	1	2	3	4	5	6	7	8	9	10	11	12
Α	Blank Contro	Blank Contro	Sample #1	Sample #1	Sample #9	Sample #9	Sample #17	Sample #17	Sample #25	Sample #25	Sample #33	Sample #33
В	1600 ng/mL	1600 ng/mL	Sample #2	Sample #2	Sample #10	Sample #10	Sample #18	Sample #18	Sample #26	Sample #26	Sample #34	Sample #34
С	800 ng/mL	800 ng/mL	Sample #3	Sample #3	Sample #11	Sample #11	Sample #19	Sample #19	Sample #27	Sample #27	Sample #35	Sample #35
D	400 ng/mL	400 ng/mL	Sample #4	Sample #4	Sample #12	Sample #12	Sample #20	Sample #20	Sample #28	Sample #28	Sample #36	Sample #36
Е	200 ng/mL	200 ng/mL	Sample #5	Sample #5	Sample #13	Sample #13	Sample #21	Sample #21	Sample #29	Sample #29	Sample #37	Sample #37
F	100 ng/mL	100 ng/mL	Sample #6	Sample #6	Sample #14	Sample #14	Sample #22	Sample #22	Sample #30	Sample #30	Sample #38	Sample #38
G	50 ng/mL	50 ng/mL	Sample #7	Sample #7	Sample #15	Sample #15	Sample #23	Sample #23	Sample #31	Sample #31	Sample #39	Sample #39
Н	Zero HA	Zero HA	Sample #8	Sample #8	Sample #16	Sample #16	Sample #24	Sample #24	Sample #32	Sample #32	Sample #40	Sample #40

Technical Data Sheet, Rev 16c, 06-25-25 - For research use only. Not intended for diagnostic or therapeutic use. Page 3



Ph: 866-588-0455 Fax: 801-588-0497 **echelon-inc.com**



References

- 1. Scott, J.E. (1995) J. Anat. 187, 259-269
- Toole, BP. Hyaluronan. (2000) Proteoglycans: Structure, Biology, and Molecular Interactions, (Renato V. Iozzo., Science pp 61-91)
- Prestwich, GD, et al. Chemical modification of hyaluronic acid for drug delivery, biomaterials and biochemical probes: The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives, Wenner-Gren International Series vol. pp 43-65, Portland Press. London and Miami
- Laurent, T.C. and Fraser. J.R.E., (1991) in Degradation of Bioactive Substances: Physiology and Pathophysiology (Henrik- sen, J.H., ed.), pp. 249-265, CRC Press, Boca Raton, FL
- Laurent, T.C. Hyaluronan as a clinical marker of pathological processes: The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives, Wenner-Gren International Series vol. pp 305-313, Portland Press, London and Miami
- 6. ARUP Laboratories. (2005) The One, Volume 1 Issue 1
- Mansson, B, et al. (1995) J. Clin Invest. 95, 1071-1077

Selected Papers using Echelon's Hyaluronic Acid ELISA

- Zhang, L. S.; Mummert, M. E. Development of a fluorescent substrate to measure hyaluronidase activity. Anal Biochem 2008, 379. 80-5.
- Yoshizaki, A.; Iwata, Y.; Komura, K.; Ogawa, F.; Hara, T.; Muroi, E.; Takenaka, M.; Shimizu, K.; Hasegawa, M.; Fujimoto, M.; Tedder, T. F.; Sato, S. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008, 172, 1650-63.
- Smith, T. J.; Hoa, N. Immunoglobulins from Patients with Graves' Disease Induce Hyaluronan Synthesis in Their Orbital Fibroblasts through the Self-Antigen, Insulin-Like Growth Factor-I Receptor. J Clin Endocrinol Metab 2004, 89, 5076-5080.
- Nieuwdorp, M.; Meuwese, M. C.; Mooij, H. L.; van Lieshout, M. H.; Hayden, A.; Levi, M.; Meijers, J. C.; Ince, C.; Kastelein, J. J.; Vink, H.; Stroes, E. S. Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis 2008.
- Nieuwdorp, M.; Holleman, F.; de Groot, E.; Vink, H.; Gort, J.; Kontush, A.; Chapman, M. J.; Hutten, B. A.; Brouwer, C. B.; Hoekstra, J. B.; Kastelein, J. J.; Stroes, E. S. Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. Diabetologia 2007, 50, 1288-93.
- 13. Meuwese, M. C.; Mooij, H. L.; Nieuwdorp, M.; van Lith, B.; Marck, R.; Vink, H.; Kastelein, J. J.; Stroes, E. S. Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia. J Lipid Res 2008.

- Guo, N.; Kanter, D.; Funderburgh, M. L.; Mann, M. M.; Du, Y.; Funderburgh, J. L. A rapid transient increase in hyaluronan synthase-2 mRNA initiates secretion of hyaluronan by corneal keratocytes in response to transforming growth factor beta. J Biol Chem 2007, 282, 12475-83.
- Gouverneur, M.; Spaan, J. A. E.; Pannekoek, H.; Fontijn, R. D.; Vink, H. Fluid shear stress stimulates incorporation of hyaluro- nan into endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol 2006, 290, H458-452.
- Cook, A. C.; Chambers, A. F.; Turley, E. A.; Tuck, A. B. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem 2006, 281, 24381-9.
- Chockalingam, P. S.; Zeng, W.; Morris, E. A.; Flannery, C. R. Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2). Arthritis Rheum 2004, 50, 2839-48.
- Brant, P. E.; Kopke-Aguiar, L.; Shigueoka, D. C.; Sales, D.;
 D'Ippolito, G.; Kouyoumdjian, M.; Borges, D. R. Anicteric cholangiopathy in schistosomiasis patients. Acta Trop 2008.
- Aoki, H.; Takada, Y.; Kondo, S.; Sawaya, R.; Aggarwal, B. B.; Kondo, Y. Evidence That Curcumin Suppresses the Growth of Malignant Gliomas in Vitro and in Vivo through Induction of Autophagy: Role of Akt and Extracellular Signal-Regulated Kinase Signaling Pathways. Mol Pharmacol 2007, 72, 29-39.
- Brands, J; Spaan, J; Van den Berg, B; Vink, H; VanTeeffelen, J. Accute attenuation of glycocalyx barrier properties increase coronary blood volume independently of coronary flow reserve. Am. J Physiol Hear Circ Physiol. 2010, 298, H515-H523.
- Declèves, A; Caron, A; Voisin, V; Legrand, A; Bouby, N; Kultti, A; Tammi, M; Flamion, B. Synthesis and Fragmentation of Hyaluronan in renal ischaemia. Nephrol Dial Transplant. 2012, 27, 3771-3781
- Hill, D; Rho, H; Kessler, S; Amin, R; Homer, C; McDonald, C; Cowman, M; de la Motte, C. Human Milk Hyaluronan Enhances Innate Defense of the Intestinal Epithelium. J. Biol. Chem. 2013, 288. 29090-29104.
- 23. Keller, K; Sun, Y; Vranka, J; Hayashi, L; Acott, T. Inhibition of Hyaluronan Synthesis Reduces Versican and Fibronectin level in Trabecular Meshwork Cells. PLoS ONE, 2012, 7(11).
- Grundman, S; Fink, K; Rabadzhieva, L; Bourgeois, N; Schwab, T; Moser, M; Bode, C; Bush, H. Perturbation of the endothelial glycocalyx in post cardiac arrest syndrome. 2012, 83, 715-720.
- Ma, J; Granton, P; Holdsworth, D; Turley, E. Oral Administration of Hyaluronan Reduces Bone Turnover in Ovariectomized Rats. J. Agric. Food Chem. 2013, 61(2), 339-345.

Related Products

Products	Catalog Number			
Assays and Reagents				
HA Sandwich ELISA	K-4800			
HA AlphaScreen Assay	K-5800			
Hyaluronidase Activity ELISA	K-6000			
Binding Proteins				
Versican G1 Domain	G-HA01			
Biotinylated Versican G1 Domain	G-HA02			
His Tagged Versican G1 Domain	G-HA03			
Select HA				
Select-HA LoLadder	HYA-LOLAD			
Select-HA HiLadder	HYA-HILAD-20			
Select-HA Mega Ladder	HYA-MGLAD-20			

Please visit our website at www.echelon-inc.com for more Hyaluronic Acid products.

TM TM

Technical Data Sheet, Rev 16c, 06-25-25 – **For research use only.** Not intended for diagnostic or therapeutic use. Page 4
